{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cohorting&page=119", "query": { "intervention": "Cohorting", "page": 119 }, "page_size": 10 }, "pagination": { "page": 119, "page_size": 10, "total_count": 11393, "total_pages": 1140, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cohorting&page=120&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cohorting&page=118&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-07T22:44:28.277Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00048048", "title": "A Study of Mircera in Anemic Patients With Chronic Kidney Disease Not Yet on Dialysis.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anemia" ], "interventions": [ { "name": "methoxy polyethylene glycol-epoetin beta [Mircera]", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 65, "start_date": "2002-03", "completion_date": "2004-11", "has_results": true, "last_update_posted_date": "2018-01-02", "last_synced_at": "2026-11-07T22:44:28.277Z", "location_count": 6, "location_summary": "Birmingham, Alabama • San Diego, California • Detroit, Michigan + 2 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Diego", "state": "California" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT00048048" }, { "nct_id": "NCT07446855", "title": "Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumours" ], "interventions": [ { "name": "AZD4956", "type": "DRUG" }, { "name": "Saruparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 180, "start_date": "2026-03-17", "completion_date": "2030-03-29", "has_results": false, "last_update_posted_date": "2026-10-27", "last_synced_at": "2026-11-07T22:44:28.277Z", "location_count": 4, "location_summary": "New York, New York • Providence, Rhode Island • Houston, Texas + 1 more", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Providence", "state": "Rhode Island" }, { "city": "Houston", "state": "Texas" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07446855" }, { "nct_id": "NCT05028634", "title": "Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Sclerosis", "Multiple Sclerosis, Relapsing-Remitting" ], "interventions": [ { "name": "Tetanus, diphtheria, and acellular pertussis vaccine", "type": "BIOLOGICAL" }, { "name": "Pneumococcal polysaccharide vaccine", "type": "BIOLOGICAL" }, { "name": "Seasonal influenza vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 63, "start_date": "2021-11-11", "completion_date": "2023-11-15", "has_results": true, "last_update_posted_date": "2025-02-11", "last_synced_at": "2026-11-07T22:44:28.277Z", "location_count": 29, "location_summary": "Palo Alto, California • Colorado Springs, Colorado • Southington, Connecticut + 26 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Southington", "state": "Connecticut" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Port Charlotte", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05028634" }, { "nct_id": "NCT05774899", "title": "CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Adenoid Cystic Carcinoma", "Metastatic Adenoid Cystic Carcinoma", "Recurrent Adenoid Cystic Carcinoma" ], "interventions": [ { "name": "CB-103", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Lenvatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Michael J. Dennis, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2023-06-01", "completion_date": "2028-06-01", "has_results": false, "last_update_posted_date": "2026-09-09", "last_synced_at": "2026-11-07T22:44:28.277Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05774899" }, { "nct_id": "NCT05144009", "title": "A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diffuse Large B-cell Lymphoma" ], "interventions": [ { "name": "Loncastuximab Tesirine", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ADC Therapeutics S.A.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 41, "start_date": "2022-06-21", "completion_date": "2024-01-22", "has_results": true, "last_update_posted_date": "2025-01-30", "last_synced_at": "2026-11-07T22:44:28.277Z", "location_count": 29, "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Aurora, Colorado + 24 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Niles", "state": "Illinois" }, { "city": "Pikeville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT05144009" }, { "nct_id": "NCT06302621", "title": "Pemigatinib + Afatinib in Advanced Refractory Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "Unresectable Solid Tumor", "Metastatic Solid Tumor", "Cholangiocarcinoma" ], "interventions": [ { "name": "Afatinib", "type": "DRUG" }, { "name": "Pemigatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2024-04-17", "completion_date": "2027-12-01", "has_results": false, "last_update_posted_date": "2026-09-23", "last_synced_at": "2026-11-07T22:44:28.277Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06302621" }, { "nct_id": "NCT02289833", "title": "A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor (HER)2 Immunohistochemistry (IHC)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Trastuzumab Emtansine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2014-12-15", "completion_date": "2018-08-20", "has_results": true, "last_update_posted_date": "2019-08-07", "last_synced_at": "2026-11-07T22:44:28.277Z", "location_count": 5, "location_summary": "Jacksonville, Florida • Chicago, Illinois • Detroit, Michigan + 2 more", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02289833" }, { "nct_id": "NCT00000649", "title": "An Open-Label, Staggered Rising Dose Cohort Study Assessing the Pharmacokinetics, Safety, and Tolerance of BI-RG-587 in Combination With Zidovudine in Patients With HIV Infection (CD4+ Cell Count < 400/mm3)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Nevirapine", "type": "DRUG" }, { "name": "Zidovudine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2008-07-30", "last_synced_at": "2026-11-07T22:44:28.277Z", "location_count": 3, "location_summary": "Birmingham, Alabama • San Diego, California • Worcester, Massachusetts", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Diego", "state": "California" }, { "city": "Worcester", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000649" }, { "nct_id": "NCT04134299", "title": "To Assess Safety, Tolerability and Physiological Effects on Structure and Function of AXA4010 in Subjects With Sickle Cell Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "To Assess the Safety and Tolerabiltiy of an Amino Acid Composition in Subjects With Sickle Cell Disease", "Anemia, Sickle Cell", "Sickle Cell Anemia", "Sickle Cell Disorders", "Sickle Cell Disease" ], "interventions": [ { "name": "AXA4010", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DIETARY_SUPPLEMENT" ], "sponsor": "Axcella Health, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 9, "start_date": "2019-09-25", "completion_date": "2021-01-11", "has_results": false, "last_update_posted_date": "2021-04-01", "last_synced_at": "2026-11-07T22:44:28.277Z", "location_count": 4, "location_summary": "Hollywood, Florida • Miami, Florida • Atlanta, Georgia + 1 more", "locations": [ { "city": "Hollywood", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Newark", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT04134299" }, { "nct_id": "NCT05709821", "title": "IMM60 and Pembrolizumab in Melanoma and NSCLC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer", "Melanoma" ], "interventions": [ { "name": "IMM60", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "iOx Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2023-11-15", "completion_date": "2024-04-22", "has_results": false, "last_update_posted_date": "2024-04-24", "last_synced_at": "2026-11-07T22:44:28.277Z", "location_count": 5, "location_summary": "Los Angeles, California • Boston, Massachusetts • Detroit, Michigan + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05709821" } ] }